New FDA Approval: Phakic Intraocular Collamer Lens (Visian ICL) for Correction of Myopia in Adults

According to the FDA's research, this implant is a good alternative for myopes who were poor candidates for Lasik either because of thin corneae or myopia outside the currently treatable range.

"The approval was based on data from a clinical study (n = 294) showing
that 95% of patients had 20/40 vision or better and 59% had 20/20 vision or
better at 3 years postimplantation."

"The ICL remains our most significant opportunity for profitable growth going forward and receipt of FDA approval represents a critical milestone," said David Bailey, President and CEO of STAAR Surgical. "Throughout the approval process, doctors' interest in our state-of-the-art lens has continued to build, driven by superior clinical outcomes, the stability and safety of the procedure and the high patient satisfaction rate.